NCT07632690Not yet recruitingPhase 3
A Randomized, Open-label, Controlled, Multicenter Phase III Clinical Trial Comparing QLC5508 Versus Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Who Have Progressed After Treatment With Novel Hormonal Agents (NHA).
Conditions
Trial Snapshot
- Phase
- Phase 3
- Status
- Not yet recruiting
- Enrollment
- 700
Study Overview
Brief Summary
This is a randomized, open-label, active-controlled, multicenter Phase III trial evaluating QLC5508 versus docetaxel in participants with metastatic castration-resistant prostate cancer (mCRPC) who have progressed after prior treatment with novel hormonal agents (NHAs). Participants are randomized to receive either QLC5508 monotherapy (experimental arm) or docetaxel (control arm). The primary objective is to compare the efficacy of QLC5508 versus docetaxel, as measured by radiographic progression-free survival (rPFS) assessed by an Independent Radiological Review Committee (IRC).
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- Male
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Male, aged ≥18 years.
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or
- •Life expectancy of at least 3 months.
- •Histologically or cytologically confirmed adenocarcinoma of the prostate without evidence of small-cell features.
- •Diagnosis of metastatic castration-resistant prostate cancer (mCRPC).
- •Prior treatment with novel hormonal agents (NHAs) and documented disease progression.
- •Adequate organ function.
- •Recovery from all reversible adverse events (AEs) related to prior anticancer therapies.
Exclusion Criteria
- •1. Prior treatment with a B7-H3-targeted therapy, or with an antibody-drug conjugate (ADC) using a topoisomerase I inhibitor (TOP1i) as the payload, or with any TOP1i-class agent.
- •2. History of or current significant cardiovascular or cerebrovascular disease.
- •Active, uncontrolled infection.
- •Concurrent or prior history of another primary malignancy
- •History of interstitial lung disease (ILD) or non-infectious pneumonitis, or current ILD/non-infectious pneumonitis
- •Current hepatic encephalopathy, hepatorenal syndrome, or cirrhosis classified as Child-Pugh class B or worse.
- •7. Known hypersensitivity or allergy to any investigational product or its excipients.
Investigators
Similar Trials
Recruiting
Phase 3
QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell CarcinomaNCT07463573Qilu Pharmaceutical Co., Ltd.466
Not yet recruiting
Phase 3
QLC7401 in Participants With Heterozygous Familial Hypercholesterolemia (HeFH)NCT07450378Qilu Pharmaceutical Co., Ltd.120
Not yet recruiting
Phase 1
First in Human Study of QLS5316 in Solid TumorsNCT07358884Qilu Pharmaceutical Co., Ltd.300
Recruiting
Phase 3
JS107 in Combination With Toripalimab and Chemotherapy for the Treatment of CLDN18.2-positive Gastric or Gastroesophageal Junction AdenocarcinomaNCT07584135NingBo Junyan Hongshi Biosciences Co., Ltd600
Not yet recruiting
Phase 3
QLC7401 Monotherapy in Non-familial Hypercholesterolemia or Mixed DyslipidemiaNCT07444086Qilu Pharmaceutical Co., Ltd.510